ABBOTT LABORATORIES
ABTNYSE · SIC 2834
$100.68
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↓ -21.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$175.9B
Enterprise Value
$202.6B
P/E
28.2
P/S
3.9
P/B
3.4
EV/EBITDA
22.1
PEG
—
FCF Yield
4.2%
Dividend Yield
2.4%
Revenue (TTM)
$45.1B
Net Income (TTM)
$6.3B
Free Cash Flow (TTM)
$7.4B
Gross Margin
—
Operating Margin
17.1%
Net Margin
13.9%
ROE
12.1%
ROIC
7.5%
Debt / Equity
0.7
Net Cash
-$26.8B
Return 1Y
-14.5%
Company profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases.
- CEO
- Robert B. Ford
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 115,000
- Headquarters
- Illinois
- Website
- abbott.com
Management & directors
- Morrone Louis H.EXECUTIVE VICE PRESIDENT
- Cushman Elizabeth C.EVP, GC AND SECRETARY
- Moreland Mary KEXECUTIVE VICE PRESIDENT
- Boudreau Philip PEVP AND CFO
- Orville Jacob ASenior Vice President
- Mccoy John A.VICE PRESIDENT AND CONTROLLER
- Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT
- Shroff EricSenior Vice President
- Earnhardt Lisa DEVP AND GROUP PRESIDENT
- Ford Robert BCHAIRMAN AND CEO
- Scoggins Christopher JEXECUTIVE VICE PRESIDENT
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-10-15
ABT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$11.2B↑ +7.8%
Diluted EPS$0.61↓ -19.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $34.6B | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $5.4B | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B |
| Net income | $4.5B | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| Diluted EPS | $2.50 | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Operating cash flow | $7.9B | $10.5B | $9.6B | $7.3B | $8.6B | $9.6B |
| Free cash flow | $5.7B | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 15.5% | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% |
| Net margin | 13.0% | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4B | $10.6B | $11.0B | $10.4B | $11.1B | $11.4B | $11.5B | $11.2B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.7B | $1.9B | $1.9B | $1.7B | $2.1B | $2.1B | $2.3B | $1.3B |
| Net income | $1.3B | $1.6B | $9.2B | $1.3B | $1.8B | $1.6B | $1.8B | $1.1B |
| Diluted EPS | $0.74 | $0.94 | $5.26 | $0.76 | $1.01 | $0.94 | $1.01 | $0.61 |
| Operating cash flow | $2.0B | $2.7B | $2.9B | $1.4B | $2.0B | $2.8B | $3.3B | $1.3B |
| Free cash flow | $1.4B | $2.1B | $2.1B | $933.0M | $1.5B | $2.3B | $2.6B | $916.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 16.1% | 17.5% | 17.4% | 16.3% | 18.4% | 18.1% | 19.6% | 12.0% |
| Net margin | 12.5% | 15.5% | 84.1% | 12.8% | 16.0% | 14.5% | 15.5% | 9.6% |
Company news
Jul 17, 2026
- 2d agoAbbott Just Showed Its Growth Engine Has More Than One Cylindertrefis.com
- 3d agoAbbott Laboratories Seen on Track for H2 Growth Acceleration, RBC Saysfinance.yahoo.com
- 3d agoABT Q2 Earnings Call Flags Stronger Second-Half Setupfinance.yahoo.com
- 3d agoCan Abbott Stock Deliver on Its Second-Half Growth Promise?trefis.com
- 3d agoAbbott discloses cyberattack on cancer diagnostics businessmedtechdive.com
- 3d agoStock Market News for July 17, 2026finance.yahoo.com
- 3d agoUS Stock Market Today: S&P 500 Futures Dip On Tariff And Energy Cost Worriesfinance.yahoo.com
- 3d agoWhy Abbott Stock Jumped Todayfool.com
Jul 16, 2026
- 3d agoStock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Offfool.com
- 4d agoAbbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Strong Growth in Key Segments and ...finance.yahoo.com
- 4d agoUpdate: Wall Street Snaps Two-Day Advance as Chip-Related Stocks Slumpfinance.yahoo.com
- 4d agoStocks Settle Lower as Chipmakers and AI Stocks Slumpbarchart.com
- 4d agoSandisk, Micron, TSMC, Abbott, AST SpaceMobile, and More Stocks That Explain Today’s Marketfinance.yahoo.com
- 4d agoUS Equity Markets End Lower Amid Tech Sell-Off, Iran's Threat to Block Red Seafinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Morrone Louis H.· EXECUTIVE VICE PRESIDENT | Tax withholding | 269 | $92.71 | $24,938.99 | filing |
| 2026-06-27 | Cushman Elizabeth C.· EVP, GC AND SECRETARY | Tax withholding | 560 | $94.12 | $52,707.20 | filing |
| 2026-05-07 | Stratton John G | Buy | 2,000 | $86.82 | $173,640.00 | filing |
| 2026-04-28 | Moreland Mary K· EXECUTIVE VICE PRESIDENT | I | 5,314 | $94.41 | $501,694.74 | filing |
| 2026-04-27 | STARKS DANIEL J | Buy | 10,000 | $92.65 | $926,537.00 | filing |
| 2026-04-24 | O'Grady Michael | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | McKinstry Nancy | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | McDew Darren W | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Kumbier Michelle | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Blount Sally E. | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Babineaux-Fontenot Claire | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Ahuja Nita | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Gonzalez Patricia P. | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Conroy Kevin T | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Stratton John G | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | STARKS DANIEL J | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-24 | Roman Michael F | Award | 2,286 | $0.00 | $0.00 | filing |
| 2026-04-23 | Boudreau Philip P· EVP AND CFO | I | 8,909 | $92.04 | $819,984.36 | filing |
| 2026-04-23 | Boudreau Philip P· EVP AND CFO | Buy | 2,200 | $91.50 | $201,300.00 | filing |
| 2026-03-23 | ORVILLE JACOB A· Senior Vice President | Award | 13,255 | $0.00 | $0.00 | filing |
| 2026-03-02 | Morrone Louis H.· EXECUTIVE VICE PRESIDENT | Sale | 1,144 | $115.58 | $132,223.52 | filing |
| 2026-03-02 | Salvadori Daniel Gesua Sive· EVP AND GROUP PRESIDENT | Sale | 885 | $115.58 | $102,288.30 | filing |
| 2026-03-02 | Shroff Eric· Senior Vice President | Sale | 709 | $115.58 | $81,946.22 | filing |
| 2026-03-02 | Moreland Mary K· EXECUTIVE VICE PRESIDENT | Sale | 613 | $115.58 | $70,850.54 | filing |
| 2026-03-02 | MCCOY JOHN A.· VICE PRESIDENT AND CONTROLLER | Sale | 585 | $115.58 | $67,614.30 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.